Featured Speakers
Insight into the market dynamics that are having the greatest impact on an industry is what drives our business and its this understanding that allows us to identify and secure the thought leaders who have a true 'vision' to offer. This is a small sample of some of those visionaries that are helping shape the future of Onco Cell Therapy.
Frank Fan
Simon Bornschein
Paul Lammers
James Trager
Robert Tighe
Gary Lee
John Rossi
Adrian Bot
Steven Kanner
Donna Rill
Emilie Gauthy
Knut Niss
Dr. Niss has served as Chief Technology Officer since March 2018. Dr. Niss joined Mustang in March 2017 as Vice President of Operations, where he initiated and oversees the establishment of Mustang’s cell therapy manufacturing facility. Prior to Mustang, Dr. Niss was Cell Therapy Asset Leader at Biogen, where he oversaw CMC-related activities for gene-edited hematopoietic stem cell and lentiviral gene therapy programs for sickle cell disease and hemophilia, respectively. Earlier in his career, Dr. Niss was Senior Technical Project Leader at Novartis’ cell therapy manufacturing facility in Morris Plains, New Jersey, where he directed the transfer and implementation of the CTL019 process from Penn to Novartis. He also served as Senior R&D Program Manager at EMD Millipore, where he established processes for the large-scale expansion of adult and pluripotent stem cells. Dr. Niss began his career in senior research positions in Pfizer’s Regenerative Medicine and Immunology groups. He holds a Ph.D. in molecular biology from Humboldt University of Berlin, and an M.S. in microbiology from the University of Göttingen in Germany. Dr. Niss completed his postdoctoral research at Boston Children’s Hospital and the Dana-Farber Cancer Institute.
John Tomtishen
Anthony Colenberg
Tatiana Novobrantseva
Kipp Weiskopf
Yaron Pereg
David Cheresh
Michael Klichinsky
Ashish Kulkarni
Sandro Matosevic
Eric Von Hofe
Charles Mooney
Albert Ribickas
Daniel Getts
Lawrence Lamb
Moa Fransson
Rafael Amado
Sheng Lin-Gibson
William Shingler
Charles Morris
Melissa Sebok
Tuval Ben-Yehezkel, PhD
Tuval Ben-Yehezkel is a scientist-entrepreneur focused on applied genomics and synthetic biology. Authored key patents, publications and book chapters in synthetic biology and genomics. Founded and secured $15.3M in funding for two biotech start-up companies.
David Cheresh
Adrienne Farid
Eric Gehrie
Daniel Getts
Vineet Kacker
Alina Lelic
Hy Levitsky
Dongfang Liu
Sandro Matosevic
Nina Möker
Charles Morris
Nicolas Poirier
Christine Probst
Martha Salinas
Alaina Schlinker
Jay Tong
Strategic Partners
From the market leading Cell Therapy and Pharmaceutical Companies to the most well respected CROs, CMOs, CDMO's, Sequencing and anymore; our Strategic Partners continue to play a pivotal role in how we help shape the future of the Cell and Gene Therapy field. For more information on how to become a strategic partner, please visit our Marketing Solutions page
About Us
LEARN
from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
NOTE
down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
INVEST
both in your company growth and your own personal development by signing up to one of our events and get started.